Background {#Sec1}
==========

Chronic periodontitis (CP) is a multifactorial inflammatory disease caused by genetic, immune, environmental, and microbiological factors and lifestyle habits \[[@CR1]--[@CR3]\]. CP is characterized by destruction of periodontal tissues, especially gingival tissue inflammation and alveolar bone resorption. Many previous studies of multiple gene interactions and pathways have not completely elucidated the biological mechanisms of CP.

Development of high-throughput experimental methods in biological studies has yielded extensive omics data. Additionally, transcriptomic studies using microarray analysis have advanced our understanding of the expression landscape for biological mechanisms of multifactorial diseases. Integration of multiple microarray datasets has generated disease-associated mRNA profiles for screening. While the experimental condition of each dataset is clinically and technically different, common differentially expressed genes (DEGs) related to CP among multiple datasets may identify key genes as potential targets for CP diagnosis and prognosis.

At present, data sharing and integration of omics data for investigating mechanisms of multifactorial diseases have gained attention. Registration of biological experimental data in public databases has also been recommended to help facilitate data sharing. Use of pooled microarray gene expression datasets is a method to reduce hybridization costs and compensate for insufficient amounts of mRNA sampling \[[@CR4]--[@CR9]\]. Many studies utilizing microarray analysis to investigate mechanisms underlying periodontitis have been conducted \[[@CR10]--[@CR25]\].

The National Center for Biotechnology Information developed the Gene Expression Omnibus (GEO) database to promote pooling and sharing of publically available transcriptomic data to facilitate biomedical research \[[@CR26]--[@CR30]\]. ArrayExpress is a public database for high-throughput functional genomic data that consists of two parts: the ArrayExpress Repository, which is the Minimum Information About a Microarray Experiment supportive public archive of microarray data, and the ArrayExpress Data Warehouse, which is a database of gene expression profiles selected from a repository that is consistently reannotated \[[@CR31]\].

In this study, we focused on gene expression in gingival tissue from CP patients. We selected and analyzed three pooled microarray platform datasets in the GEO database. The aims of the present study were to identify biomarker candidates for CP diagnosis and prognosis based on functional and molecular analyses by evaluating DEGs in gingival tissue between healthy control and CP groups.

Methods {#Sec2}
=======

In the present study, we selected microarray datasets of gingival tissue from CP patients in the GEO database and investigated clinical biomarker candidates for CP diagnosis and prognosis based on functional and molecular pathway analyses of DEGs. We selected three datasets of gingival tissue with CP, GSE10334, GSE16134, and GSE23586, using the following keywords: "chronic periodontitis," "*Homo sapiens*," "gingival tissue," and "microarray platform GPL570: Affymetrix Human Genome U133 plus 2.0 Array." These three datasets were downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). A summary of the individual studies is shown in Table [1](#Tab1){ref-type="table"}.Table 1Summary of individual studies of chronic periodontitisGEO gene set IDGSE10334GSE16134GSE23586PlatformGPL570: Affymetric Human Geneme U133 plus 2.0 ArrayNumber of Healthy Control Persons vs. Chronic Periodontitis Persons64 vs. 6369 vs. 653 vs. 3Clinical Data Healthy ControlPD ≤ 4 mm, AL ≤ 2 mm, BoP-PD ≤ 4 mm, AL ≤ 2 mm, BoP-PD ≤ 2 mm, AL = 0, BoP-, GI = 0 Chronic PeriodontitisPD \> 4 mm, AL ≥ 3 mm, BoP+PD \> 4 mm, AL ≥ 3 mm, BoP+PD ≥ 5 mm, AL ≥ 5 mm, BoP+, GI ≥ 1DiabetesNotNotNotPregnantNotNotNotSmokingNotNotNotNo systemic antibiotics or anti-inflammatory drugs for ≥6 monthsNo systemic antibiotics or anti-inflammatory drugs for ≥6 monthsNo systemic antibiotics or anti-inflammatory drugs for ≥6 monthsPubMed ID18,980,52019,835,62521,382,03524,646,639*PD* Probing Depth, *AL* Attachment Level, *BoP* Bleeding on Probing, *GI* Gingival Index

Identification of up/downregulated DEGs {#Sec3}
---------------------------------------

Up- or downregulated DEGs in the three selected datasets were identified using GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>). GEO2R is an interactive web tool and an R-based web application for comparing two groups of datasets in the GEO database, which we used to compare normal healthy control and CP groups. Common up- or downregulated DEGs in the three selected datasets were extracted. We set *p* \< 0.05 and \|fold change (FC)\| \> 2 as the cut-off criteria.

Functional analysis of DEGs {#Sec4}
---------------------------

Functional analysis of DEGs was carried out using the Gene Ontology (GO) database. Signaling pathways of DEGs were investigated based on the Kyoto Encyclopedia of Genes and Genomes (KEGG). GO and KEGG analyses were performed using the Database for Annotation Visualization and Integrated Discovery (DAVID) (<https://david.ncifcrf.gov/>). We set *p* \< 0.05 and false discovery rate (FDR) \< 5% as the cut-off criteria.

Protein-protein interaction (PPI) network construction and hub gene identification {#Sec5}
----------------------------------------------------------------------------------

The PPI network was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://string-db.org/>), which is an online repository that imports PPI data from published literature. We used default function in STRING. We calculated degrees of each protein node, and the top 12 genes were identified as hub genes.

Common molecular biomarker candidates and molecular pathways {#Sec6}
------------------------------------------------------------

Common molecular biomarker candidates for CP diagnosis and prognosis among the three datasets were investigated using Biomarker Analysis in QIAGEN's Ingenuity Pathway Analysis (IPA) software (<http://www.ingenuity.com>). Applicable biomarkers were selected based on IPA-biomarkers analysis. We set *p* \< 0.05 and \|FC\| \> 2 as the cut-off criteria.

Upstream regulators of dominant biomarker candidates {#Sec7}
----------------------------------------------------

Upstream regulators of dominant biomarker candidates and molecular pathways were analyzed using Comparison Analysis in IPA software. We set *p* \< 0.05 and FDR \< 5% as the cut -off criteria. We then illustrated molecular pathways including upstream regulators and dominant biomarker candidates.

Functional and pathway enrichment analyses of upstream regulators {#Sec8}
-----------------------------------------------------------------

Upstream regulators of each dominant biomarker candidate were analyzed based on GO and KEGG databases using DAVID. We set p \< 0.05 and FDR \< 5% as the cut-off criteria.

Results {#Sec9}
=======

We selected three gene expression microarray datasets with CP in the GEO database and investigated molecular function, PPI, hub genes, molecular pathways, and upstream regulators using DEGs to identify clinical biomarker candidates for CP diagnosis and prognosis.

Identification of up/downregulated DEGs {#Sec10}
---------------------------------------

One hundred and twenty-three common DEGs among GSE10334, GSE16134, and GSE23586 between normal healthy control and CP groups were identified using GEO2R. Specifically, 81 DEGs were significantly upregulated and 42 DEGs were significantly downregulated (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Common upregulated DEGs (*p* \< 0.05, FC \> 2) in chronic periodontitisGene SymbolGene DescriptionProbeARHGAP9pho GTPase activating protein 9224451_x\_atATP2A3ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3207522_s\_atBHLHA15basic helix-loop-helix family member A15235965_atC3complement component 3217767_atCCL18C-C motif chemokine ligand 18209924_atCD19CD19 molecule206398_s\_atCD53CD53 molecule203416_atCD79ACD79a molecule1555779_a\_atCECR1adenosine deaminase 2219505_atCHST2carbohydrate sulfotransferase 2203921_atCLDN10claudin 10205328_atCOL15A1collagen type XV alpha 1203477_atCOL4A1collagen type IV alpha 1211981_atCOL4A2collagen type IV alpha 2211964_atCSF2RBcolony stimulating factor 2 receptor beta205159_atCSF3colony stimulating factor 3207442_atCXCL12chemokine (C-X-C motif) ligand 12203666_atCXCL8chemokine (C-X-C motif) ligand 8202859_x\_atCYTIPcytohesin 1 interacting protein209606_atDENND5BDENN domain containing 5B228551_atDERL3derlin 3229721_x\_atEAF2ELL associated factor 2219551_atENPP2ectonucleotide pyrophosphatase phosphodiesterase 2209392_at, 210839_s\_atENTPD1ectonucleoside triphosphate diphosphohydrolase 1207691_x\_at, 209474_s\_atEVI2Becotropic viral integration site 2B211742_s\_atFABP4fatty acid binding protein 4203980_atFAM30Afamily with sequence similarity 30 member A206478_atFCGR2BFc fragment of IgG, low affinity IIb, receptor (CD32)210889_s\_atFCGR3BFc fragment of IgG, low affinity IIIb, receptor (CD16b)204007_atFCN1ficolin 1205237_atFCRL5Fc receptor like 5224405_atFCRLAFc receptor like A235372_atFKBP11FKBP prolyl isomerase 11219117_s\_atFPR1formyl peptide receptor 1205119_s\_atHCLS1hematopoietic cell-specific Lyn substrate 1202957_atICAM2intercellular adhesion molecule 2213620_s\_at, 204683_atICAM3intercellular adhesion molecule 3204949_atIGHMimmunoglobulin heavy constant mu209374_s\_atIGKCimmunoglobulin kappa constant216207_x\_at, 215217_atIGKV1OR2--118immunoglobulin kappa variable 1/OR2--118217480_x\_atIGLC1immunoglobulin lambda constant 1211655_atIGLJ3immunoglobulin lambda joining 3216853_x\_atIGLL5immunoglobulin lambda like polypeptide 5217235_x\_atIGLV1--44immunoglobulin lambda variable 1--44216430_x\_at, 216573_atIKZF1IKAROS family zinc finger 1227346_atIL10RAinterleukin 10 receptor, alpha204912_atIL1Binterleukin 1 beta205067_atIL2RGinterleukin 2 receptor subunit gamma204116_atIRF4interferon regulator factor 4204562_atITGALintegrin subunit alpha L1554240_a\_atITM2Cintegral membrane protein 2C221004_s\_atJCHAINjoining chain of multimeric IgA and IgM212592_atKLHL6kelch like family member 6228167_atLAX1lymphocyte transmembrane adaptor 1207734_atMMEmembrane metalloendopeptidase203434_s\_atMMP7metallopeptidase 7204259_atMS4A14-domains A1228592_atNEDD9neural precursor cell expressed developmentally down regulated 91560706_atP2RY8P2Y receptor family member 8229686_atPECAM1adhesion molecule 1208981_at, 208982_at, 208983_s\_atPIM2pim-2 proto-oncogene serine/threonine inase204269_atPIP5K1Bphosphatidylinositol-4-phosphate 5-kinase type 1 beta205632_s\_atPLPP5phospholipid phosphatase 5226150_atPROK2prokineticine232629_atRAB30RAB30, member RAS oncogene family228003_atRAC2Rac family small GTPase 2213603_s\_atRGS1Regulator of G protein signaling 1216834_atSAMSN1SAM domain, SH3 domain and nuclear localization signals 1220330_s\_atSEL1L3SEL1L family member 3212314_atSELLselectin L204563_atSELMselenoprotein M226051_atSLAMF7SLAM family member 7219159_s\_at, 234306_s\_atSPAG4sperm associated antigen 4219888_atSRGNserglycin201858_s\_at, 201859_atST6GAL1ST6 beta-galactoside alpha-2, 6-sialyltransferase 1201998_atSTAP1signal transducing adaptor family member 1220059_atTAGAPT cell activation RhoGTPase activating protein229723_at, 242388_x\_at, 1552542_s\_at, 234050_atTAGLNtransgelin205547_s\_atTHEMIS2thymocyte selection associated family member 2210785_s\_atTNFRSF17TNF superfamily member 17206641_atZBP1Z-DNA binding protein 1242020_s\_atTable 3Common downregulated DEGs (*p* \< 0.05, FC \< −2) in chronic periodontitisGene SymbolGene DescriptionProbeAADACarylacetamide deacetylase205969_atAADACL2arylacetamide deacetylase like 2240420_atABCA12ATP binding cassette subfamily A member 12215465_atAHNAK2AHNAK nucleoprotein 21558378_a\_atARG1arginase 1206177_s\_atATP6V1C2ATPase H+ transporting V1 subunit C21552532_a\_atBPIFCBPI fold containing family C1555773_atCALML5calmodulin like 5220414_atCLDN20claudin 201554812_atCWH43cell wall biogenesis 43 C-terminal homolog220724_atCYP2C18cytochrome P450 family 2 subfamily C member 18215103_atCYP3A5cytochrome P450 family 3 subfamily A member 5205765_atDSC1desmocollin 1207324_s\_atDSC2desmocollin 2204750_s\_atELOVL4ELOVL fatty acid elongase 4219532_atEPB41L4Berythrocyte membrane protein band 4.1 like 4B220161_s\_atEXPH5exophilin 5213929_at, 214734_atFLGfilaggrin215704_atFLG2filaggrin family member 21569410_atFOXN1forkhead box N11558687_a\_atFOXP2forkhead box P21555647_a\_at, 235201_at, 1555516_atGJA3gap junction protein alpha 3239572_atKRT10keratin 10207023_x\_atLGALSLgalectin like226188_atLORloricrin207720_atLY6G6Clymphocyte antigen 6 family member G6C207114_atMAP 2microtubule associated protein 2225540_atMUC15mucin 15, cell surface associated227241_at, 227238_atNEFLneurofilament light221916_at, 221805_atNEFMneurofilament medium205113_atNOS1nitric oxide synthase 1239132_atNPR3natriuretic peptide receptor 3219789_atNSG1neuronal vesicle trafficking associated 1209570_s\_atPOF1BPOF1B actin binding protein219756_s\_at, 1555383_a\_atPTGER3prostaglandin E receptor 3213933_atRORARAR related orphan receptor A210426_x\_at, 210479_s\_at, 235567_at, 226682_atRPTNrepetin1553454_atSH3GL3SH3 domain containing GRB2 like 3, endophilin A3205637_s\_atSLC16A9solute carrier family 16 member 9227506_atSPAG17sperm associated antigen 17233516_s\_atWASLWiskott-Aldrich syndrome like205809_s\_atYOD1YOD1 deubiquitinase227309_at

Functional and pathway enrichment analyses of DEGs {#Sec11}
--------------------------------------------------

The results of functional enrichment analysis of up- or downregulated DEGs in gingival tissue analyzed based on GO Biological Process (BP), Cellular Component (CC), and Molecular Function (MF) and pathway enrichment analyzed based on the KEGG pathway using DAVID are shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.Table 4Functional and pathway enrichment analyses of upregulated genes in chronic periodontitisCategoryTermGenes*p*-valueFDR (%)GOTERM_BP_FATGO:0006955\~immune responseCSF3, ITGAL, ST6GAL1, IGLV1--44, ENPP2, C3, TNFRSF17, SLAMF7, IGHM, CXCL12, CCL18, RGS1, FCGR2B, LAX1, FCN1, MS4A1, IL1B, IL2RG, CD79A, IGKC, FCGR3B, IGLC11.50E-122.31E-09GOTERM_BP_FATGO:0046649\~lymphocyte activationITGAL, IKZF1, LAX1, MS4A1, IRF4, CD79A, SLAMF7, CXCL121.69E-050.025995389GOTERM_BP_FATGO:0001775\~cell activationITGAL, IKZF1, LAX1, MS4A1, IRF4, CD79A, SLAMF7, ENTPD1,2.19E-050.033613816CXCL12GOTERM_BP_FATGO:0006935\~chemotaxisPROK2, RAC2, ENPP2, FPR1, IL1B, CXCL12, CCL184.96E-050.07634361GOTERM_BP_FATGO:0042330\~taxisPROK2, RAC2, ENPP2, FPR1, IL1B, CXCL12, CCL184.96E-050.07634361GOTERM_BP_FATGO:0002684\~positive regulation of immune system processCD19, IKZF1, C3, LAX1, IL1B, IL2RG, CD79A, CXCL125.32E-050.081770006GOTERM_BP_FATGO:0045321\~leukocyte activationITGAL, IKZF1, LAX1, MS4A1, IRF4, CD79A, SLAMF7, CXCL125.91E-050.090857027GOTERM_BP_FATGO:0048584\~positive regulation of response to stimulusCD19, C3, LAX1, IL1B, FABP4, CD79A, CXCL124.14E-040.635505695GOTERM_BP_FATGO:0007155\~cell adhesionITGAL, SELL, ICAM2, ICAM3, PECAM1, COL15A1, NEDD9,5.28E-040.809495344CLDN10, SLAMF7, ENTPD1, CXCL12GOTERM_BP_FATGO:0022610\~biological adhesionITGAL, SELL, ICAM2, ICAM3, PECAM1, COL15A1, NEDD9,5.34E-040.818570769CLDN10, SLAMF7, ENTPD1, CXCL12GOTERM_BP_FATGO:0007626\~locomotory behaviorPROK2, RAC2, ENPP2, FPR1, IL1B, CXCL12, CCL189.08E-041.387461056GOTERM_BP_FATGO:0050863\~regulation of T cell activationIKZF1, LAX1, IL1B, IL2RG, IRF40.001380162.10243667GOTERM_BP_FATGO:0050778\~positive regulation of immune responseCD19, C3, LAX1, IL1B, CD79A0.003019474.54592016GOTERM_BP_FATGO:0051249\~regulation of lymphocyte activationIKZF1, LAX1, IL1B, IL2RG, IRF40.003250164.885167435GOTERM_CC_FATGO:0005576\~extracellular regionCSF3, COL4A2, ST6GAL1, COL4A1, IGLV1--44, ENPP2, C3, MMP7, CECR1, COL15A1, IGHM, CXCL12, CCL18, PROK2, FCN1, PECAM1, IL1B, FCRLA, IGKC, ENTPD1, FCGR3B, IGLC1, SRGN3.24E-040.37812111GOTERM_CC_FATGO:0044421\~extracellular region partCSF3, COL4A2, COL4A1, C3, MMP7, CECR1, COL15A1, CXCL12, CCL18, FCN1, PECAM1, IL1B, ENTPD1, SRGN5.83E-040.680822917GOTERM_MF_FATGO:0003823\~antigen bindingIGLV1--44, FCN1, IGKC, IGHM, IGLC10.001528471.82616636KEGG_PATHWAYhsa04060:\
Cytokine-cytokine receptor interactionCSF3, IL10RA, CSF2RB, IL1B, TNFRSF17, IL2RG, CXCL12, CCL180.002417362.314177036KEGG_PATHWAYhsa04514:\
Cell adhesion molecules (CAMs)ITGAL, SELL, ICAM2, ICAM3, PECAM1, CLDN100.002443122.338574426KEGG_PATHWAYhsa04640:\
Hematopoietic cell lineageCSF3, CD19, MS4A1, IL1B, MME0.003291773.139362079*GO* Gene Ontology, *BP* Biological Process, *CC* Cellular Component, *MF* Molecular Function*KEGG* Kyoto Encyclopedia of Genes and GenomesTable 5Functional and pathway enrichment analyses of downregulated genes in chronic periodontitisCategoryTermGenes*p*-valueFDR (%)GOTERM_BP_FATGO:0008544\~epidermis developmentLOR, FLG, FOXN1, AHNAK2, KRT10, CALML54.02E-050.05644221GOTERM_BP_FATGO:0007398\~ectoderm developmentLOR, FLG, FOXN1, AHNAK2, KRT10, CALML55.84E-050.082008699GOTERM_BP_FATGO:0030216\~keratinocyte differentiationLOR, FLG, FOXN1, AHNAK23.70E-040.519046373GOTERM_BP_FATGO:0009913\~epidermal cell differentiationLOR, FLG, FOXN1, AHNAK24.78E-040.67019525GOTERM_BP_FATGO:0030855\~epithelial cell differentiationLOR, FLG, FOXN1, AHNAK20.0030620524.219242042GOTERM_CC_FATGO:0005856\~cytoskeletonLOR, NOS1, FLG, RPTN, MAP 2, KRT10, WASL, EPB41L4B, NEFL, NEFM, SPAG174.42E-040.488280071GOTERM_CC_FATGO:0001533\~cornified envelopeLOR, FLG, RPTN0.0010403851.146550038GOTERM_MF_FATGO:0005198\~structural molecule activityLOR, FLG, MAP 2, FLG2, KRT10, CLDN20, EPB41L4B, NEFL, NEFM1.15E-040.127152153GOTERM_MF_FATGO:0005200\~structural constituent of cytoskeletonLOR, EPB41L4B, NEFL, NEFM7.83E-040.865579593

Upregulated genes were significantly enriched in BP related to immune response and cell adhesion. Downregulated genes were significantly enriched in epidermis and ectoderm development and keratinocyte, epidermal cell, and epithelial cell differentiation.

Significantly enriched KEGG pathways of upregulated genes included cytokine-cytokine receptor interaction, adhesion molecules, and hematopoietic cell lineage. The pathways of downregulated genes were not significantly enriched.

PPI network construction and hub gene identification {#Sec12}
----------------------------------------------------

PPI networks of the identified DEGs were constructed using STRING, which consisted of 130 edges and 76 nodes (Fig. [1](#Fig1){ref-type="fig"}). The nodes with the higher degrees were screened as hub genes including *cluster of differentiation* (CD) *19* (*CD19*), *interleukin* (IL)*-8* (*IL8*), *CD79A*, *Fc fragment of IgG receptor* (*FCGR*) *IIIb* (*FCGR3B*), *selectin L* (*SELL*), *colony stimulating factor 3* (*CSF3*), *IL-1 beta* (*IL1B*), *FCGR IIb* (*FCGR2B*), *C-X-C motif chemokine ligand 12* (*CXCL12*), *complement component 3* (*C3*), *CD53*, and *IL-10 receptor subunit alpha* (*IL10RA*) (Table [6](#Tab6){ref-type="table"}).Fig. 1Protein-protein interaction of upregulated genes in chronic periodontitis. Network stats: number of nodes is 76, number of edges is 130. This network involves 12 hub genes, *CD19*, *IL8*, *CD79A*, *FCGR3B*, *SELL*, *CSF3*, *IL1B*, *FCGR2B*, *CXCL12*, *C3*, *CD53*, and *IL10RA*, and edgesTable 6Top 12 hub genes with higher degrees of connectivity in chronic periodontitisGene symbolGene descriptionDegreeConnected genesCD19CD19 molecule21C3, CD79A, CSF3, CXCL12, ENTPD1, FCGR2B, FCGR3B, FCRLA, ICAM3, IGLL5, IKZF1, IL10RA, IL1B, IL2RG, IL8, IRF4, ITGAL, MME, MS4A1, SELL, TNFRSF17IL8Interleukin 818C3, CCL18, CD19, CD79A, CSF3, CXCL12, FABP4, FCGR2B, FCGR3B, FPR1, ICAM3, IL1B, IL2RG, ITGAL, MME, MMP7, SELL, SRGNCD79ACD79a molecule16C3, CD19, CSF3, FCGR2B, FCGR3B, FCRLA, HCLS1, IGJ, IGLL5, IL1B, IL8, IRF4, MME, MS4A1, SEL, TNFRSF17FCGR3BFc fragment of IgG, low affinity IIIb, receptor (CD16b)14C3, CD19, CD79A, CSF3, CXCL12, ICAM3, IGLL5, IL10RA, IL1B, IL8, ITGAL, MME, SELL, SKAMF7SELLSelectin L14CD19, CD79A, CHST2, CSF3, CXCL12, FCGR2B, FCGR3B, ICAM2, ICAM3, IKZF1, IL10RA, IL1B, IL8, ITGALCSF3Colony stimulating factor 313CD19, CD79A, CSF2RB, CXCL12, FCGR2B, FCGR3B, IL10RA, IL1B, IL2RG, IL8, MME, PROK2, SELLIL1BInterleukin 1 beta11C3, CD19, CD79A, CSF3, CXCL12, FCGR2B, FCGR3B, IL8, MMP7, SELL, SRGNFCGR2BFc fragment of IgG, low affinity IIb, receptor (CD32)10C3, CD19, CD79A, CSF3, IGLL5, IL10RA, IL1B, IL8, ITGAL, SELLCXCL12Chemokine (C-X-C motif) ligand 129C3, CCL18, CD19, CSF3, FCGR3B, FPR1, IL1B1, IL8, SELLC3Complement component 38CD9, CD79A, CXCL12, FCGR2B, FCGR3B, FPR1, IL1B, IL8CD53CD53 molecule8CYTIP, EV12B, HCLS1, IL10RA, RAC2, SAMSN1, SRGN, THEMIS2IL10RAInterleukin 10 receptor, alpha8CD19, CD53, CSF3, FCGR2B, FCGR3B, HCLS1, SELL, THEMIS2

Common molecular biomarker candidates and molecular pathways {#Sec13}
------------------------------------------------------------

Common molecular biomarker candidates for diagnosis, prognosis, and other processes were identified using IPA software (Table [7](#Tab7){ref-type="table"}). Among them, *CSF3*, *CXCL12*, *IL1B*, and *transgelin* (*TAGLN*) were identified as common biomarker candidates for CP diagnosis, and *CXCL12*, *IL1B*, *membrane spanning 4-domains A1* (*MS4A1*), and *platelet and endothelial cell adhesion molecule 1* (*PECAM1*) were identified as candidates for CP prognosis. Molecular pathways of biomarker candidates are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1, Additional file [2](#MOESM2){ref-type="media"}: Figure S2, Additional file [3](#MOESM3){ref-type="media"}: Figure S3, Additional file [4](#MOESM4){ref-type="media"}: Figure S4, Additional file [5](#MOESM5){ref-type="media"}: Figure S5 and Additional file [6](#MOESM6){ref-type="media"}: Figure S6.Table 7Common molecular biomarker candidates for chronic periodontitis diagnosis, prognosis, and other processesGene symbolGene descriptionUp- or Down-regulated Gene (*p*-value)Biomarker applicationsALOX5arachidonate 5-lipoxygenaseupregulated gene (*p* \< 0.01)diagnosis, efficacyAPOC1apolipoprotein C1upregulated gene (*p* \< 0.05)prognosis, unspecified applicationARHGDIBRho GDP dissociation inhibitor betaupregulated gene (*p* \< 0.05)diagnosisBDNFbrain derived neurotrophic factordownregulated gene (*p* \< 0.01)efficacy, response to therapyCCL19C-C motif chemokine ligand 19upregulated gene (*p* \< 0.01)disease progression, unspecified applicationCCR7C-C motif chemokine receptor 7upregulated gene (*p* \< 0.05)diagnosis, efficacyCSF3colony stimulating factor 3upregulated gene (*p* \< 0.05), logFc\> 1diagnosisCXCL12C-X-C motif chemokine ligand 12upregulated gene (*p* \< 0.05), logFc\> 1diagnosis, efficacy, prognosis, unspecified applicationCXCR4C-X-C motif chemokine receptor 4upregulated gene (*p* \< 0.05)diagnosisCYGBcytoglobinupregulated gene (*p* \< 0.05)diagnosisEIF4Eeukaryotic translation initiation factor 4Edownregulated gene (*p* \< 0.05)prognosisEREGepiregulindownregulated gene (*p* \< 0.05)prognosis, response to therapyESR1estrogen receptor 1upregulated gene (*p* \< 0.01)diagnosis, disease progression, efficacy, prognosis, response to therapy, unspecified applicationIGHimmunoglobulin heavy locusupregulated gene (*p* \< 0.01)diagnosis, prognosisIL1Binterleukin 1 betaupregulated gene (*p* \< 0.05), logFc\> 1diagnosis, efficacy, prognosisKDRkinase insert domain receptorupregulated gene (*p* \< 0.05)disease progression, efficacy, prognosis, response to therapy, safetyLCKLCK proto-oncogene, Src family tyrosine kinaseupregulated gene (*p* \< 0.05)diagnosisLCP1lymphocyte cytosolic protein 1upregulated gene (*p* \< 0.01)disease progressionLGALS1galectin 1upregulated gene (*p* \< 0.05)diagnosis, prognosisLYVE1lymphatic vessel endothelial hyaluronan receptor 1upregulated gene (*p* \< 0.05)disease progressionMMP9matrix metallopeptidase 9upregulated gene (*p* \< 0.05)diagnosis, disease progression, efficacy, prognosis, unspecified applicationMS4A1membrane spanning 4-domains A1upregulated gene (*p* \< 0.05), logFc\> 1efficacy, prognosis, unspecified applicationPAPPApappalysin 1upregulated gene (*p* \< 0.05)diagnosisPDGFRBplatelet derived growth factor receptor betaupregulated gene (*p* \< 0.05)prognosis, response to therapy, unspecified applicationPECAM1platelet and endothelial cell adhesion molecule 1upregulated gene (*p* \< 0.05), logFc\> 1disease progression, efficacy, prognosisPRKCBprotein kinase C betaupregulated gene (*p* \< 0.05)diagnosis, efficacy, unspecified applicationPTPRCprotein tyrosine phosphatase, receptor type Cupregulated gene (*p* \< 0.01)diagnosis, efficacy, unspecified applicationSERPINA1serpin family A member 1upregulated gene (*p* \< 0.01)diagnosis, unspecified applicationSFRP2secreted frizzled related protein 2upregulated gene (*p* \< 0.05)diagnosisSTRA6stimulated by retinoic acid 6upregulated gene (*p* \< 0.05)diagnosisTAGLNtransgelinupregulated gene (*p* \< 0.01), logFc\> 1diagnosisTIMP4TIMP metallopeptidase inhibitor 4upregulated gene (*p* \< 0.05)diagnosis, prognosisTNFSF13BTNF superfamily member 13bupregulated gene (*p* \< 0.05)efficacy, response to therapyTPM1tropomyosin 1upregulated gene (*p* \< 0.01)diagnosisVIMvimentinupregulated gene (*p* \< 0.05)diagnosis, efficacy, prognosis, unspecified application

Upstream regulators of dominant biomarker candidates {#Sec14}
----------------------------------------------------

Upstream regulators of dominant biomarker candidates are shown in Table [8](#Tab8){ref-type="table"}. Among them, *tumor necrosis factor* (*TNF*) and *fibroblast growth factor 2* (*FGF2*) were identified as upstream regulators of dominant biomarker candidates for CP diagnosis such as *CSF3*, *CXCL12*, *IL1B*, and *TAGLN* (Fig. [2](#Fig2){ref-type="fig"}). *IL1B*, which is a biomarker candidate for CP diagnosis and prognosis, is an upstream regulator of *CSF3* and *CXCL12*.Table 8Upstream regulators of dominant biomarker candidates in chronic periodontitisDominant Biomarker CandidateUpstream RegulatorCSF3ABCG1,ADAM17,ANKRD42,ARNT,BIRC2,BIRC3,BMP4,C3AR1,C5,C5AR1,CARD9,CARM1,CD40,CEACAM1,CEBPA,CEBPB,CLEC4M,CLEC7A,CSF2,CTNNB1EP300,ETS2,EZH2,FGF2,FLI1,FOS,FOSL1GLI2,IFNG,IL10,IL15,IL17A,IL17F,IL17RA,IL1B,IL2,IL25,IL3,IL36GIL37,IL4,ITGB2JAK3,KRAS,KRT17,LECT2,LEP,LILRA2MAP3K8MYD88,NFKBIA,NFKBIE,NR1H2,OSM,PPARGPRDM1,PRKCE,PTGS2,RARA,RBPJ,SIRPA,SOCS1,STAT3,TCF4,TGM2,TLR2,TLR3,TLR4,TLR5,TLR9,TNF,TNFRSF1A,TNFRSF25,TNFSF11,TRAF6,VEGFA,WDR77,WNT5ACXCL12ACVRL1,ADAM10,APP,AR,BMP2,BSG,CCL11,CCR2,CCR5,CD14,CD40,CHUK,CREBBP,CSF3,CSF3R,CTNNB1,CXCL12,CXCR4,EBF1,EGFR,EPO,ERBB2,ERBB3,ERBB4,ESR1,ESR2,ETV5,F2R,FGF2,FHL2,GDF2,HIF1A,HMOX1,HRAS,IFNG,IFNGR1,IKBKB,IKBKG,IL10,IL15,IL17A,IL17RA,IL18,IL1A,IL1B,IL1R1,IL2,IL22,ITGA9,LTBR,MKL1,MMP1,MMP9,MYD88,NFKB2,NFKBIA,NQO1,OSM,PARP1,PRKAA1,PRKAA2,PRKCD,PTGS2,PTH,RARB,RBPJ,RELB,SNAI2,SP1,SPP1,TGFB1,TNC,TNF,TNFRSF1B,TRAF3,TWIST1,VCAN,VEGFA,VHL,WNT5A,YY1IL1BABCG1,ACTN4,ADM,ADORA2B,AGER,AGT,AHR,AIMP1,ALB,ANKRD42,ANXA1,APOE,APP,ATF3,ATG7,B4GALNT1,BCL2,BCL2L1,BCL3,BCL6,BGN,BID,BIRC3,BMP7,BRAF,BRD2,BSG,BTG2,BTK,BTRC,C3,C3AR1,C5,C5AR1,C7,C9,CAMP,CARD9,CBL,CCL11,CCL2,CCL3,CCR2,CD14,CD200,CD28,CD36,CD40,CD40LG,CD44,CD69,CDK5R1,CEBPB,CEBPD,CHUK,CLEC10A,CLEC7A,CNR2,COCH,CR1L,CR2,CREB1,CRH,CSF1,CSF2,CST3,CTNNB1,CTSG,CXCL12,CXCL8,CYBB,CYP2J2,CYR61,DICER1,DUSP1,EGF,EGFR,EGLN1,ELANE,ELN,EPHX2,ERBB2,ESR1,ESR2,F2,F2R,F2RL1,F3,FAS,FASLG,FBXO32,FCGR2A,FGF2,FN1,FOSL1,FOXO1,GAS6,GHRHR,GLI2,GNRH1,HGF,HIF1A,HMOX1,HRAS,HSPD1,HTR7,ICAM1,IFNAR1,IFNB1,IFNG,IFNGR1,IGF1,IGFBP3,IGHM,IKBKB,IKBKG,IL10,IL10RA,IL11,IL12A,IL12B,IL13,IL17A,IL17RA,IL18,IL1A,IL1B,IL1R1,IL1RN,IL2,IL22,IL25,IL26,IL27,IL27RA,IL3,IL32,IL33,IL36A,IL36B,IL36RN,IL37,IL4,IL4R,IL6R,INSR,IRAK1,IRAK2,IRAK4,IRF3,IRF4,IRF6,IRF8,ITCH,ITGA4,ITGA5,ITGA9,ITGAM,ITGAX,ITGB1,ITGB3,JAG2,JAK2,JUN,KLF2,KNG1,KRAS,KRT17,LBP,LCN2,LECT2,LEP,LGALS1,LGALS9,LIF,LILRB4,LPL,LTA,LY6E,LYN,MAP 2 K3,MAP 3 K7,MAP 3 K8,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MEFV,MET,MIF,MTOR,MVP,MYD88,NCOR2,NFKB1,NFKBIA,NFKBIB,NLRC4,NOS1,NOS2,NR1H2,NR3C1,NR3C2,NT5E,OSM,P2RX4,PARP1,PDE5A,PDK2,PDPK1,PDX1,PELI1,PF4,PIK3R1,PIM3,PLA2G2D,PLAT,PLAU,PLG,PPARG,PRDM1,PRKCD,PRKCE,PROC,PSEN1,PTAFR,PTGER4,PTGES,PTGS2,PTPN6,PTX3,RAC1,RARB,RBPJ,RC3H1,RELA,RELB,RETNLB,RGS10,RHOA,RIPK1,RORA,RUNX3,S1PR3,SCD,SELP,SELPLG,SERPINE2,SFRP5,SFTPD,SGPP1,SIRT1,SMAD3,SMAD4,SMAD7,SMARCA4,SOCS1,SOCS6,SOD2,SP1,SPHK1,SPI1,SPP1,SREBF1,ST1,ST8SIA1,STAT1,STAT3,STK40,SYK,TAC1,TAC4,TARDBP,TCF3,TCL1A,TGFB1,TGFBR2,TGIF1,TGM2,THBD,TICAM1,TICAM2,TIRAP,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR9,TNC,TNF,TNFAIP3,TNFRSF1A,TNFRSF9,TNFSF10,TNFSF11,TNFSF12,TP63,TPSAB1/TPSB2,TRAF3,TRAF6,TREM1,TSC22D1,TSC22D3,TWIST1,TXN,TYROBP,UCN,VCAN,VEGFA,WNT5A,WT1,WWTR1,XDH,YY1,ZC3H12A,ZFP36MS4A1BCOR,GATA1,IL4,IRF4,IRF8,POU2F2,SPI1,TFE3,TGFB3,TXNPECAM1APLN,ATG7,CD44,CYR61,ENG,ERG,FAS,FGFR3,GATA1,GATA2,GATA6,HBB,HMOX1,IFNG,IL12A,IL17A,IL2,IL6,JAK2,KLF2,KLF4,KRAS,LEP,LIF,MAP 2 K1,MAPK14,MOG,MTOR,NAMPT,PIM3,PLCG1,PLG,PPARG,RELA,SOX2,SOX4,STAT1,STAT3,TGFA,TGFB1,TGFB2,THBD,TLR3,TNF,VEGFA,WT1TAGLNACVRL1,ADAMTS12,APP,BMP2,BMP4,CREBBP,ELK1,ERBB2,F2R,FGF2,FHL2,FN1,FOXA1,FOXA2,GATA6,GNA15,HDAC1,HDAC3,HDAC4,HMGA1,HOXC8,HOXD3,HRAS,HTT,KLF4,MAPK14,MDK,MKL1,MKL2,MMP1,NOTCH1,PDLIM2,PPARG,RHOA,ROCK2,RUNX2,S1PR3,SMAD3,SMAD7,SMARCA2,SMARCA4,SP1,SP3,SPHK1,STAT3,TAZ,TGFB1,TGFB2,TGFB3,TGFBR2,TNF,TP63,VHL,YAP1,YY1Fig. 2Biomarker candidates and upstream regulators in chronic periodontitis. The pathway shows relationships between biomarker candidates *CSF3*, *CXCL12*, *IL1B*, *MS4A1*, *PECAM1*, and *TAGLN* and their upstream regulators *TNF*, *FGF2*, and *IL1B*

Functional and pathway enrichment analyses of upstream regulators {#Sec15}
-----------------------------------------------------------------

The results of functional and pathway enrichment analyses are shown in Additional file [7](#MOESM7){ref-type="media"}: Table S1, Additional file [8](#MOESM8){ref-type="media"}: Table S2, Additional file [9](#MOESM9){ref-type="media"}: Table S3, Additional file [10](#MOESM10){ref-type="media"}: Table S4, Additional file [11](#MOESM11){ref-type="media"}: Table S5 and Additional file [12](#MOESM12){ref-type="media"}: Table S6.

In BP, upstream regulators of *CSF3* were significantly enriched in positive regulation of the biosynthetic process and the macromolecule metabolic process (Additional file [7](#MOESM7){ref-type="media"}: Table S1). Upstream regulators of *CXCL12* were significantly enriched in positive regulation of the biosynthetic process, the cellular biosynthetic process, and the nitrogen compound metabolic process (Additional file [8](#MOESM8){ref-type="media"}: Table S2). Upstream regulators of *IL1B* were significantly enriched in response to wounding, regulation of programmed cell death, regulation of cell death, defense response, and inflammatory response (Additional file [9](#MOESM9){ref-type="media"}: Table S3). Upstream regulators of *MS4A1* were significantly enriched in regulation of gene-specific transcription, regulation of transcription from RNA polymerase II promoter, and positive regulation of gene-specific transcription (Additional file [10](#MOESM10){ref-type="media"}: Table S4). Upstream regulators of *PECAM1* were significantly enriched in positive regulation of the macromolecule metabolic process, the biosynthetic process, and signal transduction (Additional file [11](#MOESM11){ref-type="media"}: Table S5). Additionally, *TAGLN* was significantly enriched in positive regulation of the macromolecule biosynthetic process, the nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, and the biosynthetic process (Additional file [12](#MOESM12){ref-type="media"}: Table S6).

In KEGG pathways, upstream regulators of *CSF3* were significantly enriched in cytokine-cytokine receptor interaction and the Toll-like receptor signaling pathway (Additional file [7](#MOESM7){ref-type="media"}: Table S1). Upstream regulators of *CXCL12* were significantly enriched in cytokine activity, growth factor activity, and cytokine binding (Additional file [8](#MOESM8){ref-type="media"}: Table S2). Upstream regulators of *IL1B* were significantly enriched in the Toll-like receptor signaling pathway and cytokine-cytokine receptor interaction (Additional file [9](#MOESM9){ref-type="media"}: Table S3). Upstream regulators of *MS4A1* were significantly enriched in the intestinal immune network for IgA production (Additional file [10](#MOESM10){ref-type="media"}: Table S4). Upstream regulators of *PECAM1* were significantly enriched in cytokine activity, growth factor activity, and transcription regulator activity (Additional file [11](#MOESM11){ref-type="media"}: Table S5). Additionally, upstream regulators of *TAGLN* were significantly enriched in the transforming growth factor beta (*TGF-β*) signaling pathway (Additional file [12](#MOESM12){ref-type="media"}: Table S6).

Discussion {#Sec16}
==========

CP is a multifactorial disease associated with genetic, environmental, and microbiological factors, lifestyle habits, and systemic diseases. The pathological mechanisms of CP are complex and have not yet been fully delineated.

Microarray analysis of mRNA expression is a powerful tool to elucidate screening profiles and is capable of efficiently narrowing down candidate genes associated with multifactorial diseases and investigating underlying mechanisms of diseases and biomarkers for diagnosis and prognosis \[[@CR4]--[@CR9], [@CR32], [@CR33]\]. Furthermore, the clinical application of biomarkers at an early stage is important for global health \[[@CR32]\].

In this study, we focused on mRNA expression data in gingival tissue from CP patients using pooled datasets in the GEO database to elucidate characteristics of DEGs and biomarker candidates for CP diagnosis and prognosis.

Eighty-one common upregulated DEGs and 42 downregulated DEGs were found. Upregulated genes were enriched in processes associated with immunity in GO BP, which comprise immune response, regulation of the immune response, regulation of the immune system process, and positive regulation of the immune system process and cytokine-cytokine receptor interaction, cell adhesion molecules, and hematopoietic cell lineage in the KEGG pathway. Downregulated genes were enriched in epidermis and ectoderm development and keratinocyte, epidermal cell, and epithelial cell differentiation, and no KEGG pathway was significant. The association between immunity and CP was assumed.

Our analysis also suggested that *CD19*, *IL8*, *CD79A*, *FCGR3B*, *SELL*, *CSF3*, *IL1B*, *FCGR2B*, *CXCL12*, *C3*, *CD53*, and *IL10RA* are hub genes for the pathological pathway of CP.

Guo et al reported several hub genes of periodontitis using microarray analyses \[[@CR5]\]. Similar to their report, we also identified *SLAMF7*, *CD79A*, *MMP7*, *IL1B*, *LAX1*, *IGLJ3*, *CSF3* and *TNFRSF17* as DEGs. Common results of GO enrichment analysis were immune response, chemotaxis, and taxis. Common KEGG pathways included cytokine-cytokine receptor interaction and cell adhesion molecules (CAMs). Common hub genes were *IL8*, *IL1B*, *CXCL12*, *CSF3*, *CD79A*, and *SELL*.

Song et al reported several DEGs and functional enrichment analysis of inflammation and bone loss process in periodontitis. With comparing the results of our present study to them \[[@CR12]\], common DEGs were *CD19*, *formyl peptide receptor 1* (*FPR1*), *interferon regulatory factor 4* (*IRF4*), and *IL1B*. Common results of GO enrichment analysis in upregulated DEGs were cell activation, positive regulation of immune system process, extracellular region, extracellular region part, and antigen binding, while those in downregulated DEGs were epidermis development, keratinocyte differentiation, epidermal cell differentiation, structural molecule activity, and structural constituent of the cytoskeleton. Common KEGG pathways of upregulated DEGs were cytokine-cytokine receptor interaction, hematopoietic cell lineage, and CAMs appear to be related to inflammation and bone loss process in periodontitis.

We also identified *CSF3*, *CXCL12*, *IL1B*, and *TAGLN* as biomarker candidates for CP diagnosis and *CXCL12*, *IL1B*, *MS4A1*, and *PECAM1* as biomarker candidates for CP prognosis. *CSF3*, *CXCL12*, *IL1B*, and *MS4A1* are related to immune response. *CXCL12* and *MS4A1* are related to lymphocyte activation and cell activation. *PECAM1* is related to phagocytosis and endocytosis. *TAGLN* is a TGF-β1-inducible gene \[[@CR34]\].

Furthermore, *TNF* and *FGF2* are common upstream regulators of all biomarker candidates for CP diagnosis. Mitogen-activated protein kinase 1 (*ERK*, *MAPK1*) is a common upstream regulator of all biomarker candidates for CP prognosis. Additionally, *IL1B* is one of the upstream regulators of *CSF3* and *CXCL12*. Furthermore, vascular endothelial growth factor A and prostaglandin-endoperoxide synthase 2 are upstream regulators of *CSF3*, *CXCL12*, and *IL1B*.

Among biomarker candidates and hub genes, the association of *CD53*, *CD79A*, *MS4A1*, *PECAM1*, and *TAGLN* with CP has not been previously reported. Potential reason is that biological information in databases for bioinformatics analysis is continuously updated as omics data become available and developed functions of software improves. *CD53* plays a role in the regulation of growth. *CD79A* encodes the Ig-alpha protein of the B-cell antigen component. *MS4A1* plays a role in the development and differentiation of B-cells into plasma cells. *PECAM1* is a member of the immunoglobulin superfamily and involved in leukocyte migration. Furthermore, *CD53*, *CD79A*, *MS4A1*, and *PECAM1* are associated with immune responses to infection by microorganisms. Lastly, *TAGLN* is a member of the calponin family and expressed in vascular smooth muscle \[[@CR34]\].

Biomarker candidates such as *CSF3*, *CXCL12*, *IL1B*, *MS4A1*, and *PECAM1*, upstream regulators such as *TNF* and *FGF2*, and hub genes such as *CD53*, *CD79A*, *MS4A1* and *PECAM1* are related to immune response and inflammation.

Conclusions {#Sec17}
===========

In summary, our study, which analyzed pooled omics datasets with distinct clinical and experimental baselines, provided new clues for elucidating common genetic factors of multifactorial diseases such as CP. Data mining and integration with sharing and using pooled omics data could be useful tools to investigate biomarker candidates for diagnosis and prognosis of diseases in clinical practice and to understand complicated underlying molecular mechanisms. We also identified key genes related to CP pathogenesis such as *CSF3*, *CXCL12*, *IL1B*, *TAGLN*, *CD19*, *IL8*, and *CD79A* and upstream genes of biomarker candidates such as *TNF* and *FGF2*, which could provide potential targets for CP diagnosis. For clinical application, a combination of biomarkers would likely be necessary for CP diagnosis or prognosis. Bioinformatics analysis of pooled microarray datasets is useful for screening to investigate biomarker candidates of CP. Further validation of these predicted molecular biomarkers obtained from bioinformatics analysis using experimental research approaches such as qRT-PCR is necessary.
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